Testclear

testclear.com

Testclear is an industry leader in drug testing solutions which has been operating for 23+ years. We sell only proven solutions to help individuals pass drug tests worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SANA BIOTECHNOLOGY RAISES MORE THAN $700M FOR CELL, GENE THERAPY EFFORTS

Sana Biotechnology | June 23, 2020

news image

A startup company developing in vivo and ex vivo cell therapies has raised a significant chunk of funding for its initial financing from life science and technology venture capital as well as pension plans and others.Seattle-based Sana Biotechnology said Tuesday that it had raised more than $700 million from a wide range of investors, including ARCH Venture Partners, Flagship Pioneering, the Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, the Alaska Permanent Fund, ...

Read More

Medical

HEALTHPARTNERS, HELIX PARTNER TO CREATE DNA TESTING PROGRAM THAT HELPS FAMILIES BETTER UNDERSTAND THEIR GENETIC HEALTH

Helix | March 09, 2022

news image

HealthPartners and leading genomics company, Helix, are launching myGenetics, a population genomics program that will provide important health information to families across Minnesota and surrounding states. The myGenetics program hopes to enroll more than 100,000 participants over four years. Genomic data generated will be integrated with patient health records and shared during their personal clinical care. Through the partnership, HealthPartners will be able to identify risk ea...

Read More

Cell and Gene Therapy

CELLISTIC AND CELYAD ONCOLOGY ANNOUNCE GMP CELL THERAPY MANUFACTURING OPERATIONS TRANSACTION

Cellistic and Ncardia | September 20, 2022

news image

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...

Read More

Industrial Impact

QIAGEN AND NEURON23 PARTNER TO DEVELOP NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC FOR NOVEL PARKINSON’S DISEASE DRUG

QIAGEN and Neuron23™ | September 15, 2022

news image

QIAGEN and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase inhibitor for Parkinson’s disease. Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of bi...

Read More
news image

SANA BIOTECHNOLOGY RAISES MORE THAN $700M FOR CELL, GENE THERAPY EFFORTS

Sana Biotechnology | June 23, 2020

A startup company developing in vivo and ex vivo cell therapies has raised a significant chunk of funding for its initial financing from life science and technology venture capital as well as pension plans and others.Seattle-based Sana Biotechnology said Tuesday that it had raised more than $700 million from a wide range of investors, including ARCH Venture Partners, Flagship Pioneering, the Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, the Alaska Permanent Fund, ...

Read More
news image

Medical

HEALTHPARTNERS, HELIX PARTNER TO CREATE DNA TESTING PROGRAM THAT HELPS FAMILIES BETTER UNDERSTAND THEIR GENETIC HEALTH

Helix | March 09, 2022

HealthPartners and leading genomics company, Helix, are launching myGenetics, a population genomics program that will provide important health information to families across Minnesota and surrounding states. The myGenetics program hopes to enroll more than 100,000 participants over four years. Genomic data generated will be integrated with patient health records and shared during their personal clinical care. Through the partnership, HealthPartners will be able to identify risk ea...

Read More
news image

Cell and Gene Therapy

CELLISTIC AND CELYAD ONCOLOGY ANNOUNCE GMP CELL THERAPY MANUFACTURING OPERATIONS TRANSACTION

Cellistic and Ncardia | September 20, 2022

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...

Read More
news image

Industrial Impact

QIAGEN AND NEURON23 PARTNER TO DEVELOP NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC FOR NOVEL PARKINSON’S DISEASE DRUG

QIAGEN and Neuron23™ | September 15, 2022

QIAGEN and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase inhibitor for Parkinson’s disease. Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of bi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us